<DOC>
	<DOCNO>NCT00667953</DOCNO>
	<brief_summary>This study design evaluate side effect Gleevec give combination Temzolomide ; learn drug work body whether combination useful treat patient melanoma .</brief_summary>
	<brief_title>Study Temzolomide Gleevec Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically confirm melanoma metastatic unresectable standard curative palliative measure exist longer effective Prior chemotherapy , immunotherapy , radiation therapy ( Phase I portion ) , cytokine , biologic , vaccine therapy permit , however prior treatment temozolomide Measurable disease ECOG performance status &lt; = 2 Life expectancy great 3 month No prior treatment temozolomide imatinib mesylate Organ allografts Prior radiotherapy , prior intratumor injection therapy , area measurable disease use target indicator lesion , unless progression occur site measurable disease develop outside treatment area Pregnancy lactation History second cancer Known hypersensitivity temozolomide imatinib Use experimental therapy within 3 week prior baseline evaluation do prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Temzolomide</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Advanced melanoma</keyword>
	<keyword>Phase II</keyword>
</DOC>